伊伐莫替尼治疗中重度活动性溃疡性结肠炎的疗效与安全性:一项II期研究
AMBER2是一项在中国、美国及欧洲63个中心开展的双盲、安慰剂对照II期试验,164例中重度活动性溃疡性结肠炎患者按1:1:1:1随机接受伊伐莫替尼8mg每日一次、4mg每日两次、4mg每日一次或安慰剂治疗8周,随后进入8周延长期。第8周临床应答率在8mg每日一次组为46.3%(P=0.066)、4mg每日两次组为46.3%(P=0.059)、4mg每日一次组为43.9%(P=0.095),安慰剂组为26.8%;临床缓解率分别为22.0%(P=0.020)、24.4%(P=0.013)、24.4%(P=0.011),安慰剂组为4.9%。伊伐莫替尼总体耐受性良好。
要点
- 伊伐莫替尼8mg每日一次组第8周临床应答率46.3%,安慰剂组26.8%(P=0.066)。
- 伊伐莫替尼4mg每日两次组第8周临床应答率46.3%,安慰剂组26.8%(P=0.059)。
- 伊伐莫替尼4mg每日一次组第8周临床应答率43.9%,安慰剂组26.8%(P=0.095)。
核心结论
- 伊伐莫替尼在中重度活动性溃疡性结肠炎患者中显示出临床疗效且耐受性良好,可能成为有前景的新治疗选择。
研究设计与样本
- AMBER2为双盲、安慰剂对照II期试验,在中国、美国及欧洲63个临床中心开展。
- 共164例患者按1:1:1:1随机接受口服伊伐莫替尼8mg每日一次、4mg每日两次、4mg每日一次或安慰剂治疗8周,随后进入8周延长期。
- 主要终点为第8周临床应答率。
- 采用Hochberg法将研究总体I类错误控制在α=0.1。
主要发现
- 共146例(89.0%)患者完成8周治疗。
- 第8周临床应答率:8mg每日一次组46.3%(P=0.066)、4mg每日两次组46.3%(P=0.059)、4mg每日一次组43.9%(P=0.095),安慰剂组26.8%。
- 第8周临床缓解率:8mg每日一次组22.0%(P=0.020)、4mg每日两次组24.4%(P=0.013)、4mg每日一次组24.4%(P=0.011),安慰剂组4.9%。
- 初始8周期间,治疗中出现的不良事件在伊伐莫替尼治疗患者中发生率为43.9%至48.8%,安慰剂组为39.0%,以轻度为主。
- 未发生死亡、主要不良心血管事件或血栓栓塞事件。
关键数值与推荐
- 第8周临床应答率:伊伐莫替尼8mg每日一次组46.3%(P=0.066),4mg每日两次组46.3%(P=0.059),4mg每日一次组43.9%(P=0.095),安慰剂组26.8%。
- 第8周临床缓解率:伊伐莫替尼8mg每日一次组22.0%(P=0.020),4mg每日两次组24.4%(P=0.013),4mg每日一次组24.4%(P=0.011),安慰剂组4.9%。
- 初始8周治疗中出现的不良事件发生率:伊伐莫替尼治疗患者43.9%至48.8%,安慰剂组39.0%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Current therapies for ulcerative colitis (UC) fail to achieve satisfactory disease control. Selective inhibition of Janus kinase (JAK) type 1 may improve clinical outcomes in patients with UC while avoiding the side effects associated with pan-JAK inhibition. The safety and efficacy of the selective JAK1 inhibitor ivarmacitinib (formerly SHR0302) were evaluated in patients with moderate-to-severe, active UC. METHODS: AMBER2 was a double-blind, placebo-controlled, phase II trial conducted at 63 clinical centers in China, the United States, and Europe. Patients (N = 164) were randomized 1:1:1:1 to receive oral ivarmacitinib 8 mg once daily (QD), 4 mg twice daily (BID), or 4 mg QD, or placebo for 8 weeks, followed by an 8-week extension period. The primary endpoint was clinical response rate at week 8. Hochberg's procedure was used to control the study-wise type 1 error at alpha=0.1. RESULTS: A total of 146 (89.0%) patients completed 8 weeks of treatment. Week 8 clinical response rates were significantly higher in the 8 mg QD (46.3%; P = .066), 4 mg BID (46.3%; P = .059), and 4 mg QD (43.9%; P = .095) groups vs placebo (26.8%). Week 8 rates of clinical remission were 22.0% (P = .020), 24.4% (P = .013), and 24.4% (P = .011) in the 3 ivarmacitinib treatment groups, respectively, vs 4.9% for placebo. During the initial 8-week period, treatment-emergent adverse events occurred in 43.9% to 48.8% of ivarmacitinib-treated patients and in 39.0% of the placebo group, and were predominantly mild. There were no deaths, or major adverse cardiovascular or thromboembolic events. CONCLUSION: Ivarmacitinib demonstrated clinical efficacy and was well tolerated in patients with moderate-to-severe, active, UC. Ivarmacitinib represents a promising new treatment for moderate-to-severe UC. CLINICALTRIALS: gov number, NCT03675477.
引用
- Chen B, Zhong J, Li X, et al. Efficacy and Safety of Ivarmacitinib in Patients With Moderate-to-Severe, Active, Ulcerative Colitis: A Phase II Study. Gastroenterology. 2022. PMID: 35963369. doi:10.1053/j.gastro.2022.08.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。